Camber Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Camber Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,175,000	Closed	-$184M	–	44
2020 Q4	$184M	Sell	1,175,000 -125,000	-10%	-$16.1M	6.44%	4
2020 Q3	$149M	Sell	1,300,000 -100,000	-7%	-$10.8M	7.85%	3
2020 Q2	$157M	Sell	1,400,000 -250,000	-15%	-$26.5M	8.99%	3
2020 Q1	$148M	Buy	1,650,000 +775,000	+89%	+$76.1M	8.85%	1
2019 Q4	$94.6M	Buy	875,000 +25,000	+3%	+$2.67M	4.82%	6
2019 Q3	$83.2M	Buy	850,000 +450,000	+113%	+$50.7M	4.38%	7
2019 Q2	$52.4M	Sell	400,000 -200,000	-33%	-$25.8M	2.44%	18
2019 Q1	$81.1M	Hold	600,000	–	–	4.04%	9
2018 Q4	$58.4M	Buy	+600,000	New	+$70.9M	2.77%	14
2017 Q3	–	Sell	-200,000	Closed	-$24.3M	–	35
2017 Q2	$24.3M	Buy	+200,000	New	+$23.3M	1.18%	24

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Camber Capital Management's ALXN Position: Q1 2021 in Review

Camber Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,175,000 shares — an estimated $184M sold.

Camber Capital Management first reported a position in ALXN in Q2 2017 and held it in 10 quarters. The position peaked at $184M in Q4 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Camber Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Camber Capital Management sold 1,175,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $184M.
Camber Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 10 quarters.
Camber Capital Management's Alexion Pharmaceuticals position peaked at $184M in Q4 2020.
753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Camber Capital Management's 13F filing for Q1 2021, filed 17 May 2021.